Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Anti-glutamate Receptor GluR3B for Diagnosis, Research and Drug Discovery in Epilepsy
Yeda R&D Co. Ltd Israel flag Israel
Abstract ID:
A monoclonal antibody against GluR3B, a peptide found in epilepsy patients, and especially in patients suffering from intractable, resistant forms of the disease, could be used in diagnosis kits as well as in drug development for this form of \"autoimmune....
Contact Galit Mazooz, ph.d.
Participants
You
Email me a copy of this message

A monoclonal antibody against GluR3B, a peptide found in epilepsy patients, and especially in patients suffering from intractable, resistant forms of the disease, could be used in diagnosis kits as well as in drug development for this form of "autoimmune epilepsy".



Applications


1. Producing a new kit for epilepsy patients, able to detect GluR3b Ab's and thus GluR3-mediated neuropathology
The anti GluR3B monoclonal Ab could be used for developing a new diagnostic kit to detect neuropathogenic human anti-GluR3B in serum and CSF of patients with epilepsy. The patient's GluR3B Ab's would compete and displace the GluR3B mAb's of its ligand: the GluR3B peptide. The presence of GluR3B Ab's in a patient, would indicate that autoimmunity against GluR3 may underlie the patient's neuropathology and a) would suggest the initiation of an immune-based therapy b) prevent useless and dangerous brain surgery c) prevent non-effective medication.

2. Drug design for GluR3-mediated neuropathology
The unique GluR3B monoclonal antibody could be used to screen a potential drug for 'Autoimmune Epilepsy'. The GluR3B monoclonal antibody could be used to screen for a molecule (i.e. Anti-idiotypic antibodies) that would block the GluR3 autoantibodies and their detrimental neuropathological effects.

3. Research tool for a kaleidoscope of purposes, including:



  • Detection of the GluR3 glutamate receptor subtype on various target cells.



  • Studies of the properties of the Glutamate/AMPA receptor subtype 3.



  • Studies of the Glutamate-liked agonist activity of the GluR3B monoclonal antibody, and of the GluR3 receptor ion channel gating properties.



  • Production of an animal model of 'Autoimmune Epilepsy'.



  • Studies of neuronal death caused by binding of the GluR3 autoantibody to glutamate/AMPA receptors.



  • Studies of behavioral impairments caused by binding of the GluR3 autoantibody to glutamate/AMPA receptors.
    Advantages
    Technology's Essence
    Scientists from the Weizmann Institute of Science have discovered a unique anti-GluR3B monoclonal antibody Glu149/29/61.
    Licensing Status

FEATURED
Last Updated May 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE
CORPORATION